Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating crizanlizumab for sickle cell disease-related priapism has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Priapism
• Sickle Cell Disease

Drugs mentioned

• Crizanlizumab (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Priapism | Phase 2 | Status: COMPLETED | Results posted: 2025-03-10